Early access
Sign in
Taking peoplePhase 1/2

Testing HS235 added to usual treatment in adults with pulmonary arterial hypertension

Tests HS235 against placebo, added to usual care, in adults with pulmonary arterial hypertension.

Key facts

Who runs it
35Pharma Inc.
Where
Greifswald and Heidelberg, GermanySee the 2 sitesAlso in 4 other countries, 15 sites
Registry title
Phase 1b/2 Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIde)
Status
Recruiting
Phase
Phase 1/2
People taking part
50 people, planned
Started
21 Oct 2026
Expected to end
31 Mar 2028
Type of study
Interventional
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pulmonary arterial hypertension (PAH), high blood pressure in the lungs. It tests HS235 against placebo added to the PAH treatment they already take.

Age
18 years or older
Sex
Women and men can join

Where in Germany

Also in 4 other countries, 15 sites

  • Universitaetsmedizin Greifswald KöRGreifswald, GermanyNot yet recruiting
  • Thoraxklinik Heidelberg gGmbHHeidelberg, GermanyNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Testing HS235 added to usual treatment in adults with pulmonary arterial hypertensionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
12 November 2026